Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 2761-2767

  Un, Frank ^a   Qi, Christina ^a   Prosser, Megan ^a   Wang, Norby ^a   Zhou, Bingsen ^a   Bronner, Christian ^b   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b INSERM   (France)

Author keywords

Checkpoint; Hydroxyurea; ICBP90; Lytic path; Ribonucleotide reductase

Indexed keywords

HYDROXYUREA; LUCIFERASE; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR 1CBP90; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEINS; DEOXYRIBONUCLEOTIDES; ENZYME INDUCTION; GENE SILENCING; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; KB CELLS; PROMOTER REGIONS (GENETICS); RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS);

EID: 33746750913     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hehlmann R: Current CML therapy: progress and dilemma. Leukemia 17: 1010-1012, 2003.
2. Reichard P: Ribonucleotid reductase: the evolution of allosteric regulation. Arch Biochem Biophys 597: 149-155, 2002.
3. Elledge SJ, Zhou Z, Allen JB and Navas TA: DNA damage and cell cycle regulation of ribonucleotide. BioEssays 75: 333-339, 1993.
4. Nyberg KA, Michelson RJ, Putnam CW and Weinert TA: Toward maintaining the genome: DNA damage and replication checkpoints. Ann Rev Genet 36: 617-656, 2002.
5. Zhou B, Mi S, Mo X, Shih J, Tsai J, Hu E, Hsu M, Kay K and Yen Y: Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anticancer Res 22: 1369-1378, 2002.
6. Muto M, Kanari Y, Kubo E, Takabe T, Kurihara T, Fujimori A and Tatsumi K: Targeted disruption of NP95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks. J Biol Chem 277: 34549-34555, 2002.
7. Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, Bellocq JP, Oudet P and Bronner C: ICPB90, a novel human CCAAT binding protein, involved in the regulatin of topoisomerase IIalpha expression. Cancer Res 60: 121-128, 2000.
8. Zhou B and Yen Y: Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses. Cytogenet Cell Genet 95: 52-59, 2001.
9. Zhu L, Somio G, Zhou B, Shao J, Bedell V, Slovak ML, Liu X, Luo J and Yen Y: Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 4: 787-798, 2005.
10. Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Ishikawa H and Sava H: Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9: 131-142, 2004.
11. Jeanblanc M, Mouslin M, Hopfner R, Bathami K, Martinet N, Abbady AQ, Siffert JC, Mathieu E, Muller CD and Bronner C: The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 24: 7337-7345, 2005.
12. Lagergren J and Reichard P: Purine deoxyribonucleosides counteract effects of hydroxyurea on deoxyribonucleoside triphosphate pools and DNA synthesis. Biochem Pharmacol 18: 2985-2991, 1987.
13. Mousli M, Hopfner R, Abbady AQ, Monte D, Jeanblanc M, Oudet P, Louis B and Bronner C: ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer 89: 120-127, 2003.